Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

AstraZeneca Plans Albemarle County, Virginia, Production Operations

10/20/2025
Global biopharmaceutical company AstraZeneca plans to establish operations in Albemarle County, Virginia. The $4.5 billion project is expected to create 600 jobs.

The investment will include the construction of a drug substance manufacturing facility focused on chronic diseases and a facility dedicated to antibody-drug conjugates focused on therapies for oncology indications located at the Rivanna Futures Site.

“With our $4.5 billion investment in Virginia, the largest in AstraZeneca’s history, we are not only building a state-of-the-art manufacturing facility, but also driving life sciences innovation and economic growth,” said AstraZeneca Chief Executive Officer Pascal Soriot. “This new facility will create thousands of jobs and strengthen America’s national security and health sovereignty. I also want to thank Governor Youngkin and his team for their energy and vision. We have found in Virginia an amazing team that moves at incredible speed to build a better future for this Commonwealth and the American people.”

AstraZeneca will be eligible to receive an MEI Commission-approved special appropriation of up to $191.3 million based upon an investment of $4 billion and the creation of 500 jobs for the drug substance manufacturing facility focused on chronic diseases, subject to approval by the Virginia General Assembly. The facility dedicated to antibody-drug conjugates will be eligible for a grant from the Commonwealth’s Opportunity Fund.

“AstraZeneca has never shied away from the hardest challenges: cancer, obesity, heart disease, and more. Their $4.5 billion investment in Virginia is a powerful vote of confidence in what our Commonwealth has to offer,” noted Secretary of Commerce and Trade Juan Pablo Segura. “Six hundred Virginians will soon join AstraZeneca in the fight to deliver hope and healing to patients. AstraZeneca’s decision shows that with our top talent, ideal location, and pro-business environment, Virginia is the place where innovation and opportunity come together to build a healthier future for all Americans.”

The Virginia Economic Development Partnership (VEDP) worked with Albemarle County and the General Assembly’s Major Employment and Investment Project Approval Commission to secure the projects.

AstraZeneca main research and development focuses on oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. The company produces a range of prescription medicines, biologics, and vaccines, including widely known drugs such as Tagrisso, Farxiga, and Symbicort.

Exclusive Research